Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Mortality
ICU
Hospitalization
Serious outcomes
Cases
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Quercetin  COVID-19 treatment studies for Quercetin  C19 studies: Quercetin  Quercetin   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 quercetin studies
00.250.50.7511.251.51.752+Di Pierro (RCT)86%0.14 [0.01-2.72]death0/763/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)67%0.33 [0.01-7.74]death0/211/21Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.02-1.82]0/974/9779% improvementOnal (RCT)24%0.76 [0.10-5.81]death1/5210/395CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment24%0.76 [0.10-5.81]1/5210/39524% improvementArslan (RCT)92%0.08 [0.01-0.79]cases1/719/42CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP92%0.08 [0.01-0.79]1/719/4292% improvementAll studies76%0.24 [0.07-0.79]2/22023/53476% improvement4 quercetin COVID-19 studiesc19quercetin.com Sep 18, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 2.35Effect extraction pre-specifiedFavors quercetinFavors control 00.250.50.7511.251.51.752+Di Pierro (RCT)86%0.14 [0.01-2.72]0/763/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)67%0.33 [0.01-7.74]0/211/21Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.02-1.82]0/974/9779% improvementOnal (RCT)24%0.76 [0.10-5.81]1/5210/395CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment24%0.76 [0.10-5.81]1/5210/39524% improvementAll studies58%0.42 [0.09-1.82]1/14914/49258% improvement3 quercetin COVID-19 mortality resultsc19quercetin.com Sep 18, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 1.16Favors quercetinFavors control 00.250.50.7511.251.51.752+Di Pierro (RCT)94%0.06 [0.00-1.00]0/768/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)67%0.33 [0.01-7.74]0/211/21Tau​2 = 0.00; I​2 = 0.0%Early treatment87%0.13 [0.02-1.05]0/979/9787% improvementOnal (RCT)94%0.06 [0.00-0.98]0/5214/395CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment94%0.06 [0.00-0.98]0/5214/39594% improvementAll studies90%0.10 [0.02-0.52]0/14923/49290% improvement3 quercetin COVID-19 ICU resultsc19quercetin.com Sep 18, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 2.72Favors quercetinFavors control 00.250.50.7511.251.51.752+Di Pierro (RCT)68%0.32 [0.14-0.70]hosp.7/7622/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)67%0.33 [0.01-7.74]hosp.0/211/21Tau​2 = 0.00; I​2 = 0.0%Early treatment68%0.32 [0.15-0.69]7/9723/9768% improvementAll studies68%0.32 [0.15-0.69]7/9723/9768% improvement2 quercetin COVID-19 hospitalization resultsc19quercetin.com Sep 18, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.93Favors quercetinFavors control 00.250.50.7511.251.51.752+Di Pierro (RCT)86%0.14 [0.01-2.72]death0/763/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)67%0.33 [0.01-7.74]death0/211/21Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.02-1.82]0/974/9779% improvementOnal (RCT)24%0.76 [0.10-5.81]death1/5210/395CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment24%0.76 [0.10-5.81]1/5210/39524% improvementAll studies58%0.42 [0.09-1.82]1/14914/49258% improvement3 quercetin COVID-19 serious outcomesc19quercetin.com Sep 18, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 1.16Effect extraction pre-specifiedFavors quercetinFavors control 00.250.50.7511.251.51.752+Arslan (RCT)92%0.08 [0.01-0.79]1/719/42CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP92%0.08 [0.01-0.79]1/719/4292% improvementAll studies92%0.08 [0.01-0.63]1/719/4292% improvement1 quercetin COVID-19 case resultc19quercetin.com Sep 18, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 2.40Favors quercetinFavors control 00.250.50.7511.251.51.752+Di Pierro (RCT)74%0.26 [0.12-0.57]5/2119/21Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment74%0.26 [0.12-0.57]5/2119/2174% improvementAll studies74%0.26 [0.12-0.57]5/2119/2174% improvement1 quercetin COVID-19 viral clearance resultc19quercetin.com Sep 18, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 3.37Favors quercetinFavors control 00.250.50.7511.251.51.752+Di Pierro (RCT)86%0.14 [0.01-2.72]death0/763/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)67%0.33 [0.01-7.74]death0/211/21Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.02-1.82]0/974/9779% improvementOnal (RCT)24%0.76 [0.10-5.81]death1/5210/395CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment24%0.76 [0.10-5.81]1/5210/39524% improvementArslan (RCT)92%0.08 [0.01-0.79]cases1/719/42CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP92%0.08 [0.01-0.79]1/719/4292% improvementAll studies76%0.24 [0.07-0.79]2/22023/53476% improvement4 quercetin COVID-19 Randomized Controlled Trialsc19quercetin.com Sep 18, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 2.35Effect extraction pre-specifiedFavors quercetinFavors control 00.250.50.7511.251.51.752+Di Pierro (RCT)86%0.14 [0.01-2.72]0/763/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)67%0.33 [0.01-7.74]0/211/21Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.02-1.82]0/974/9779% improvementOnal (RCT)24%0.76 [0.10-5.81]1/5210/395CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment24%0.76 [0.10-5.81]1/5210/39524% improvementAll studies58%0.42 [0.09-1.82]1/14914/49258% improvement3 quercetin COVID-19 RCT mortality resultsc19quercetin.com Sep 18, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 1.16Favors quercetinFavors control 00.250.50.7511.251.51.752+Di Pierro (RCT)86%0.14 [0.01-2.72]death0/763/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)67%0.33 [0.01-7.74]death0/211/21Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.02-1.82]0/974/9779% improvementAll studies79%0.21 [0.02-1.82]0/974/9779% improvement2 quercetin COVID-19 peer reviewed trialsc19quercetin.com Sep 18, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.41Effect extraction pre-specifiedFavors quercetinFavors control 00.250.50.7511.251.51.752+Di Pierro (RCT)86%0.14 [0.01-2.72]death0/763/76Improvement, RR [CI]TreatmentControlDi Pierro (RCT)94%0.06 [0.00-1.00]ICU0/768/76Di Pierro (RCT)68%0.32 [0.14-0.70]hosp.7/7622/76Di Pierro (RCT)67%0.33 [0.01-7.74]death0/211/21Di Pierro (RCT)67%0.33 [0.01-7.74]ICU0/211/21Di Pierro (RCT)67%0.33 [0.01-7.74]hosp.0/211/21Di Pierro (RCT)74%0.26 [0.12-0.57]viral+5/2119/21Di Pierro (RCT)89%0.11 [0.01-1.94]viral+0/214/21Onal (RCT)24%0.76 [0.10-5.81]death1/5210/395CT​1Onal (RCT)94%0.06 [0.00-0.98]ICU0/5214/395CT​1Onal (RCT)68%0.32 [0.04-2.29]no disch.1/5224/395CT​1Arslan (RCT)92%0.08 [0.01-0.79]cases1/719/42CT​1quercetin COVID-19 outcomesc19quercetin.com Sep 18, 2021Favors quercetinFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit